Price
No data yet.
Social Signal Score
Revenue
$31.1KCompany Profile
- CEO
- David H. Weinstein
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Beta
- 0.35
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.11
Financials
LNAI has only 11 quarterly periods on file — the charts below show the full history available.
Revenue
$31.1K+48.3%Net Income
$-2.01MEBITDA
$-2.11MFree Cash Flow
$-1.84MEPS (diluted)
$-0.44Shares Outstanding (diluted)
4.62M+460.7%Operating Expenses
$26.57MCash & Debt
$1.71BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $52.0K | $-3.56M | $-1.06 |
| 2024 | $0.00 | $-178.01M | $-86.24 |
| 2023 | $0.00 | $-88.43M | $-72.80 |
| 2022 | $0.00 | $-39.68M | $-56.80 |
| 2021 | $0.00 | $-113.43M | $-172.80 |
| 2020 | $0.00 | $-26.72M | $-45.36 |
Valuation
LNAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-20.00%Social Signal Score
Mentions (4)
- Newsprnewswire.com·27d ago·Negative
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets SACRAMENTO, Calif., Sept. 22, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement…
View source ↗ - Newsprnewswire.com·33d ago·Negative
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI 5.1-fold enrichment using NIH Tox21 data validates structure-based AChE screening as OpenAI and Anthropic highlight growing dual-use AI risks SACRAMENTO, Calif., Sept. 16, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics subsidiary, supporting the development of structure-based screening tools for…
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.
View source ↗ - Newsprnewswire.com·53d ago·Negative
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.
View source ↗
Earnings
Thu, Nov 12(in 3 weeks)
Estimates and results for LNAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in LNAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.